Q-omics provides the consensus-scored CD58 profile across patient tissues and cancer cell-line models. CD58 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CD58 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CD58 RNA expression shows 18,804 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, HNSC, and UVM as cancer lineages where CD58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD58 survival associations across molecular data types. CD58 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD58 RNA expression–survival associations across cancer types. High CD58 expression shows unfavorable associations in LIHC, LGG, UVM, STAD and SCLC, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CD58 RNA expression.
This table summarizes CD58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD58 shows lower tumor expression in KICH and LUAD and higher tumor expression in HNSC, KIRC, THCA and LIHC. The HNSC box plot shows higher CD58 RNA expression in tumor versus normal tissue (log2 FC = +0.915, t-test p < 0.001).
This table shows molecular features associated with CD58 in patient tissues and cancer cell lines. In patient samples, CD58 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CD58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BREAST.
